Helix deal reinforces Bio-Rad's position in autoimmune tests
This article was originally published in Clinica
Executive Summary
The acquisition last month of Helix Diagnostics by Bio-Rad Laboratories has underscored the Hercules, California company's growing position in the rapidly expanding autoimmune disease monitoring and diagnosis segment. West Sacramento, California-based Helix is known for developing and launching the first commercially successful EIA for the detection of anti-nuclear antibodies, a kit used to screen patients for systemic autoimmune disease.